Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. Issue 11 (2nd June 2020)

• Record Type: Journal Article
• Authors: Prausmüller, Suriya; Arfsten, Henrike; Spinka, Georg; Freitag, Claudia; Bartko, Philipp E.; Goliasch, Georg; Strunk, Guido; Pavo, Noemi; Hülsmann, Martin
• Is Part Of: Journal of the American Heart Association. Volume 9:Issue 11(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-06-02
• Subjects: biomarker -- heart failure -- neprilysin -- neprilysin activity; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.119.015071
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Neprilysin is a transmembrane endopeptidase involved in the breakdown of a variety of vasoactive peptides and serves as a therapeutic target in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate the relationship of circulating neprilysin with neurohumoral activation and the impact of plasma neprilysin activity on prognosis in HFrEF. Methods and Results: A total of 369 chronic HFrEF patients were enrolled prospectively. Plasma neprilysin concentration and activity were determined by a specific ELISA and a fluorometric method. The association between plasma neprilysin and heart failure (HF) severity, neurohumoral activation, ie norepinephrine and absolute renin concentration, as well as all‐cause mortality was assessed. Median plasma neprilysin concentrations and activity levels were 413 pg/mL (interquartile range 0–4111) and 2.36 nmol/mL per minute (interquartile range 1.16–4.59). No correlation could be shown between plasma neprilysin concentrations and activity ( r s =0.09, P =0.088). Plasma neprilysin activity correlated with HF severity reflected by New York Heart Association stage ( P =0.003) and tertiles of N‐terminal pro‐B‐type natriuretic peptide ( P <0.001), whereas neprilysin concentrations did not ( P =0.220; P =0.849). There was no relevant relationship between plasma neprilysin concentrations and activity, with neurohumoral activation reflected by absolute renin concentration ( r s =−0.02, P =0.648; r s =0.03, P =0.574) or norepinephrine levels ( r s =−0.06, P =0.248; r s =0.20, P <0.001). Neither circulating neprilysin concentrations nor activity were associated with outcome. Conclusions: Plasma neprilysin concentrations and activity are not directly related to neurohumoral activation, indicating that neprilysin regulation is either more complex or not correctly mirrored by circulating neprilysin as a biomarker. Circulating neprilysin concentrations and activity were not associated with overall survival, implicating limited prognostic value of plasma neprilysin measurements in HFrEF patients.